-+ 0.00%
-+ 0.00%
-+ 0.00%

Guggenheim Maintains Buy on Zevra Therapeutics, Raises Price Target to $25

Benzinga·05/08/2026 13:29:27
Listen to the news
Guggenheim analyst Eddie Hickman maintains Zevra Therapeutics (NASDAQ:ZVRA) with a Buy and raises the price target from $23 to $25.